Levin Capital Strategies L.P. Sells 58,305 Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS)

Levin Capital Strategies L.P. lowered its stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) by 17.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,459 shares of the company’s stock after selling 58,305 shares during the quarter. Levin Capital Strategies L.P.’s holdings in Alpha Tau Medical were worth $710,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DRTS. Caprock Group LLC purchased a new stake in shares of Alpha Tau Medical during the second quarter valued at about $59,000. Aptus Capital Advisors LLC increased its holdings in shares of Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. raised its position in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares during the last quarter. USAdvisors Wealth Management LLC purchased a new position in shares of Alpha Tau Medical in the 1st quarter valued at approximately $30,000. Finally, Private Advisor Group LLC acquired a new stake in Alpha Tau Medical in the 4th quarter worth approximately $176,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Trading Down 1.5 %

Shares of Alpha Tau Medical stock opened at $2.24 on Tuesday. The stock has a market cap of $156.06 million, a PE ratio of -5.46 and a beta of 0.77. The firm has a fifty day moving average price of $2.18 and a 200 day moving average price of $2.49. Alpha Tau Medical Ltd. has a 1 year low of $1.75 and a 1 year high of $3.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.66 and a quick ratio of 11.60.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Equities research analysts predict that Alpha Tau Medical Ltd. will post -0.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on DRTS shares. Piper Sandler restated an “overweight” rating and issued a $7.00 target price on shares of Alpha Tau Medical in a research note on Thursday, August 15th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, August 20th.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.